<DOC>
	<DOCNO>NCT00669812</DOCNO>
	<brief_summary>RATIONALE : Giving chemotherapy peripheral blood stem cell transplant stop growth cancer cell stop divide kill . After treatment , stem cell collect patient 's blood store . More chemotherapy give prepare bone marrow stem cell transplant . The stem cell return patient replace blood-forming cell destroy chemotherapy . PURPOSE : This phase II trial study high-dose chemotherapy give together peripheral blood stem cell transplant treat patient intestinal T-cell lymphoma .</brief_summary>
	<brief_title>High-Dose Chemotherapy Given Together With Peripheral Blood Stem Cell Transplant Treating Patients With Intestinal T-Cell Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - To assess efficacy toxicity intensive high-dose chemotherapy ( alternate I 'VE regimen intermediate-dose methotrexate ) follow autologous peripheral blood stem cell transplantation treatment patient intestinal T-cell lymphoma . Secondary - To assess toxicity regimen large population patient . - To provide coordinated approach treatment patient . - To register patient unfit protocol chemotherapy pathological part study . OUTLINE : This multicenter study - Chemotherapy : Patients receive CHOP chemotherapy comprise cyclophosphamide IV 15 minute , doxorubicin hydrochloride IV , vincristine IV day 1 . Patients also receive oral prednisolone day 1-5 . After recover CHOP chemotherapy , patient receive I 'VE chemotherapy comprise epirubicin hydrochloride IV day 1 etoposide IV 2 hour ifosfamide IV continuously day 21-23 . Patients also receive methotrexate IV 24 hour day 21 . Treatment repeat every 28 day 3 course absence disease progression unacceptable toxicity . - Consolidation therapy : On day 77 , stem cell collect patient marrow clear disease . After completion chemotherapy , patient complete remission receive carmustine IV day 105 , cytarabine IV etoposide IV day 106-109 , melphalan IV day 110 . These patient undergo autologous peripheral blood stem cell transplantation day 112 . Prior study treatment , patient undergo biopsy gut confirm diagnosis blood sample take . Both blood tissue sample may use study . After recovery treatment , patient follow monthly 4 month , bimonthly 1 year , every 3 month 1 year , every 4 month 1 year , every 6 month 1 year , annually thereafter . Peer Reviewed Funded Endorsed Cancer Research UK .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Intestinal Neoplasms</mesh_term>
	<mesh_term>Enteropathy-Associated T-Cell Lymphoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Newly confirm diagnosis intestinal Tcell lymphoma/ enteropathytype Tcell lymphoma accord follow WHO classification : Usual phenotype CD3 , CD7positive ; CD5 , CD4 , CD8negative ; CD30positive Complete surgical resection allow PATIENT CHARACTERISTICS : Unsupported neutrophil ≥ 1,500/mm^3 unless attribute lymphomatous bone marrow infiltration Unsupported platelet ≥ 100,000/mm^3 unless attribute lymphomatous bone marrow infiltration Creatinine clearance ≥ 50 mL/min Alkaline phosphatase ≤ 2.5 time upper limit normal ( ULN ) Bilirubin ≤ 2.5 time ULN Left ventricular ejection fraction ≥ 50 % Not pregnant nursing Fertile patient must use effective contraception ≥ 1 month completion study treatment Patients serious concomitant medical psychiatric condition would preclude tolerate plan treatment enter registration study No known hepatitis B , hepatitis C , HIV positivity No active uncontrolled cardiovascular disease No abnormal EKG previous history cardiac problem No severe impairment cardiac function No active malignancy within past 5 year except cervical intraepithelial neoplasia localize skin cancer PRIOR CONCURRENT THERAPY : See Disease Characteristics Prior diagnostic emergency surgical procedure allow More 5 year since prior treatment malignancy No prior chemotherapy radiotherapy treatment lymphoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>small intestine lymphoma</keyword>
	<keyword>stage I adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage II adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage III adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
</DOC>